Findings from plasmaMATCH study where Guardant360® was used
Home » Findings from plasmaMATCH study where Guardant360® was used

GH AMEA on Social MediaFindings from plasmaMATCH study where Guardant360® was used
Findings from plasmaMATCH study where Guardant360® was used
Findings from plasmaMATCH study where Guardant360® was used
Lancet Oncology

Recently published in The Lancet Oncology, results from the plasmaMATCH trial of women with advanced breast cancer demonstrate that the Guardant360 liquid biopsy accurately identifies actionable mutations in genes such as HER2 and AKT1 and can guide appropriate treatment selection. https://lnkd.in/guTdfVf

Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at clientservices@guardantamea.com or contact us on WhatsApp: +65 8940 0360.

Guardant360®. Test. Take Action.

Open chat
Message us